Table 2.
Summary of clinical outcomes for each study.
| Study | Complication | Revision | Pain (VAS) | ROM | Function score | Walking speed | |
|---|---|---|---|---|---|---|---|
| Liu 2021 | HTO | 0 | 0 | NC | 134.2 ± 2.7 | 93.5 ± 5.0 (Lysholm) | NC |
| UKA | 0 | 0 | 133.4 ± 3.1 | 93.9 ± 4.1 (Lysholm) | |||
| Watanabe 2021 | HTO | NC | NC | NC | 131.9 ± 8.2 | 80.8 ± 17.5 (Lysholm) | NC |
| UKA | 129.5 ± 12.3 | 82.4 ± 16.4 (Lysholm) | |||||
| Rodkey 2021 | HTO | 24 | 4 | NC | NC | NC | NC |
| UKA | 6 | 37 | |||||
| Lin 2021 | HTO | 2 | NC | NC | NC | 86.58 ± 4.28 (HSS) | NC |
| UKA | 1 | 87.72 ± 2.80 (HSS) | |||||
| Jin 2021 | HTO | 1 | 7 | NC | 138.1 ± 3.7 | 86.6 ± 11.5 (HSS) | NC |
| UKA | 0 | 2 | 135.7 ± 10.0 | 88.8 ± 13.2 (HSS) | |||
| Zhang 2021 | HTO | 0 | 0 | 0.5 ± 0.7 | NC | 90.6 ± 8.7 (HSS) | NC |
| UKA | 2 | 1 | 0.5 ± 0.6 | 91.7 ± 7.2 (HSS) | |||
| Hou 2020 | HTO | NC | NC | 1.8 ± 0.9 | 121.1 ± 2.7 | 81.9 ± 14.3 (HSS) | NC |
| UKA | 1.9 ± 0.8 | 135.2 ± 1.6 | 82.6 ± 12.9 (HSS) | ||||
| Chen 2020 | HTO | 0 | 0 | NC | NC | 90.6 ± 2.0(Lysholm) | NC |
| UKA | 0 | 0 | 91.5 ± 1.7(Lysholm) | ||||
| Jacquet 2020 | HTO | 5 | 0 | 1.0 ± 0.5 | NC | 61 ± 7(KSS) | NC |
| UKA | 0 | 0 | 0.9 ± 0.4 | 60 ± 9(KSS) | |||
| Song 2019 | HTO | NC | 14 | NC | 135.3 ± 12.3 | 73.9 ± 15.3(KSS) 30.6 ± 16.6(WOMAC) | NC |
| UKA | 11 | 126.8 ± 13.3 | 71.0 ± 10.5(KSS) 32.9 ± 10.2(WOMAC) | ||||
| Koh 2019 | HTO | 0 | NC | 2.6 ± 1.3 | NC | 24.2 ± 11.4(WOMAC) | NC |
| UKA | 0 | 2.2 ± 1.6 | 13.9 ± 6.4(WOMAC) | ||||
| Kim 2019 | HTO | NC | NC | 4.7 | NC | NC | NC |
| UKA | 5.2 | ||||||
| Ryu 2018 | HTO | 0 | NC | 2.2 ± 1.2 | NC | 16.5 ± 17.5(WOMAC) | NC |
| 87.4 ± 12.0(Lysholm) | |||||||
| UKA | 0 | 1.5 ± 1.7 | 14.9 ± 16.9(WOMAC) | ||||
| 89.2 ± 10.2(Lysholm) | |||||||
| Cho 2018 | HTO | 0 | NC | NC | 149.4 ± 9.4 | 95.1 ± 7.6(KSS) | NC |
| UKA | 1 | 146.8 ± 12.7 | 96.3 ± 8.5(KSS) | ||||
| Zhao 2017 | HTO | NC | NC | 3.54 ± 0.50 | 126.13 ± 1.45 | 82.76 ± 8.13(HSS) | NC |
| UKA | 2.45 ± 0.47 | 128.94 ± 1.37 | 93.09 ± 8.69(HSS) | ||||
| Maxwell 2017 | HTO | 18 | 19 | NC | NC | 21 (FJS) | NC |
| UKA | 3 | 1 | 67(FJS) | ||||
| Krych 2017 | HTO | NC | 13 | NC | NC | 80.2 ± 11.8(Lysholm) | NC |
| UKA | 11 | 90.0 ± 11.0(Lysholm) | |||||
| Jeon 2017 | HTO | 2 | NC | 3.3077 ± 2.61119 | NC | 50.1727 ± 17.12898(IKDC) | NC |
| UKA | 1 | 2.2381 ± 2.16575 | 56.8667 ± 15.70697(IKDC) | ||||
| Petersen 2016 | HTO | 2 | NC | NC | NC | 7/10/2/4(HSS, Excellent/Good/Fair/Poor) | NC |
| UKA | 1 | 14/7/2/2(HSS, Excellent/Good/Fair/Poor) | |||||
| Tuncay 2015 | HTO | 6 | 0 | NC | NC | OWHTO 83.95(HSS) | NC |
| Demo-HTO 83.51(HSS) | |||||||
| UKA | 1 | 3 | 90.00(HSS) | ||||
| Yim 2013 | HTO | 3 | NC | NC | 138.8 ± 4.7 | 89.6 ± 8.7(Lysholm) | NC |
| UKA | 2 | 130.0 ± 8.8 | 90.3 ± 7.7(Lysholm) | ||||
| Takeuchi 2010 | HTO | 2 | 0 | NC | 146 ± 5.9 | 89 ± 7.6(KSS) | NC |
| UKA | 1 | 2 | 127 ± 16 | 88 ± 7.7(KSS) | |||
| Borjesson 2005 | HTO | NC | NC | 0 (0–2) (Borg-scale) | 121 | 37(36–39) (BOA) | NC |
| UKA | 0 (0–2) (Borg-scale) | 121 | 37(31–39) (BOA) | ||||
| Stukenborg 2001 | HTO | 9 | 10 | NC | 117(85–135) | 76(29–100) (KSS) | NC |
| UKA | 2 | 6 | 103(35–140) | 74(31–94) (KSS) | |||
| Weale 1994 | HTO | NC | 17 | 9/21 (no/mild) | NC | 31(BKS) | NC |
| UKA | 5 | 12/15 (no/mild) | 34(BKS) | ||||
| Weidenhielm 1992 | HTO | 2 | NC | 25 (No pain) | NC | 37 ± 2(BOA) | 1.29 ± 0.16 |
| UKA | 1 | 28 (No pain) | 38 ± 2(BOA) | 1.3 ± 0.18 | |||
| Ivarsson 1991 | HTO | NC | NC | 6.3 ± 2.1 (100 mm Analogous) | 121 ± 11 | 78 ± 19(Lysholm) | 1.35 ± 0.42 |
| UKA | 4.1 ± 2.9 (100 mm Analogous) | 112 ± 13 | 91 ± 11(Lysholm) | 1.20 ± 0.24 | |||
| Jefferson 1989 | HTO | NC | NC | NC | NC | NC | 1.02 ± 0.19 |
| UKA | 0.99 ± 0.21 | ||||||
| Broughton 1986 | HTO | 17 | 10 | 23 (No or mild) | NC | 21 (BKS good number) | NC |
| UKA | 5 | 3 | 34 (No or mild) | 32 (BKS good number) |